Sapanisertib
- Generic Name
- Sapanisertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C15H15N7O
- CAS Number
- 1224844-38-5
- Unique Ingredient Identifier
- JGH0DF1U03
- Background
Sapanisertib has been used in trials studying the treatment of HCC, Solid Tumor, Gliosarcoma, Liver Cancer, and Glioblastoma, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors
- First Posted Date
- 2014-07-22
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 44
- Registration Number
- NCT02197572
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2014-06-10
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 83
- Registration Number
- NCT02159989
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
- Conditions
- Endometrial Clear Cell AdenocarcinomaEndometrial Serous AdenocarcinomaRecurrent Uterine Corpus CancerSolid NeoplasmStage IIIB Fallopian Tube Cancer AJCC v7Stage IIIB Ovarian Cancer AJCC v6 and v7Ovarian Endometrioid AdenocarcinomaOvarian Clear Cell CystadenocarcinomaOvarian Mucinous CystadenocarcinomaOvarian Serous Cystadenocarcinoma
- Interventions
- First Posted Date
- 2014-05-20
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT02142803
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Charlestown, Massachusetts, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT02133183
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 118
- Registration Number
- NCT02049957
- Locations
- 🇺🇸
Henry Ford Medical Center, Novi, Michigan, United States
🇺🇸Texas Oncology, P.A. - Tyler, Tyler, Texas, United States
🇫🇷Institut Sainte Catherine, Avignon, Vaculuse, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.